The FDA on August 5, 2022, approved NUBEQA® tablets in combination with Docetaxel for adult patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC). NUBEQA® is a product of Bayer HealthCare Pharmaceuticals Inc.
Bottom Ad
Advertisement
Subscribe
